Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.

导出 LinkOut

翻译打印收藏纠错

作者： Li-Min,Zhao ^[1] ; Xie-Hui,Chen ^[1] ; Mei,Qiu ^[2]

作者单位： Department of Geriatric Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China. ^[1] Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China. ^[2]

关键词 COVID- 19 DPP4 (dipeptidyl peptidase 4) inhibitors SGLT2I death glp1 agonists type 2 diabetes mellitus

主题词糖尿病, 2型(Diabetes Mellitus, Type 2);人类(Humans);降血糖药(Hypoglycemic Agents)

DOI 10.3389/fendo.2021.825100

PMID 35082762

发布时间 2022-01-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Frontiers in endocrinology

2021年12卷

825100页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.

Frontiers in endocrinology

相似文献

Frontiers in endocrinology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.

Frontiers in endocrinology

相似文献

Frontiers in endocrinology

相关期刊

检索历史清除